Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response
Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease
Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival
Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients
Breast Cancer Risk Increases With Repeated CT Imaging
Scatter Radiation from Mammography Presents No Increased Cancer Risk
MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas
NCI-Approved CTEP Trials For the Month of December
FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.